Field effectiveness of vaccination against tick-borne encephalitis. - Wikidata - wikimedia - TriplyDB

Field effectiveness of vaccination against tick-borne encephalitis.

Field effectiveness of vaccination against tick-borne encephalitis.

http://www.wikidata.org/entity/Q43040713

about

Mechanism and significance of cell type-dependent neutralization of flaviviruses Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile disease Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections Tick-borne encephalitis from eating goat cheese in a mountain region of Austria Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype Degrees of maturity: the complex structure and biology of flaviviruses Tick-borne encephalitis virus replication, intracellular trafficking, and pathogenicity in human intestinal Caco-2 cell monolayers Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis Zika virus-like particle (VLP) based vaccine [Important vector-borne infectious diseases among humans in Germany. Epidemiological aspects].Estimating the annual burden of tick-borne encephalitis to inform vaccination policy, Slovenia, 2009 to 2013 Forecasting risk of tick-borne encephalitis (TBE): using data from wildlife and climate to predict next year's number of human victims.Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines.A national case-control study identifies human socio-economic status and activities as risk factors for tick-borne encephalitis in Poland Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.Correlation of TBE incidence with red deer and roe deer abundance in Slovenia.Antibody-mediated neutralization of flaviviruses: a reductionist view.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial The Willingness to Pay for Vaccination against Tick-Borne Encephalitis and Implications for Public Health Policy: Evidence from Sweden.The Burden of Tick-Borne Encephalitis in Disability-Adjusted Life Years (DALYs) for Slovenia.Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.Vaccination and tick-borne encephalitis, central Europe.Low coverage and predictors of vaccination uptake against tick-borne encephalitis in Slovenia.A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Advances in vaccination against tick-borne encephalitis.Tick-borne encephalitis: What travelers should know when visiting an endemic country.Recommendations for tick-borne encephalitis vaccination from the Central European Vaccination Awareness Group (CEVAG).Tick-borne encephalitis in children: an update on epidemiology and diagnosis.Tick-borne encephalitis: Clinical findings and prognosis in adults.Vaccines and vaccination against tick-borne encephalitis.Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice.Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice.Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus.Review of tick-borne encephalitis and vaccines: clinical and economical aspects.

P2860

Q23032973-56AA66ED-65CA-40DC-958D-8D38D315B6F5 Q24273313-FB1D7ACA-BDAB-46FC-BEDD-DC65259A1E6B Q24289014-A3B797CE-9888-4C08-A540-BDDEDE6A138D Q24457206-A36CEF6B-5451-472B-81EE-93AAF2C55A1B Q24737461-7F51621C-85CB-403A-9BE7-C7465CE6B940 Q26252060-267C5A05-7136-4CB2-A21C-FD416F36BFED Q26824712-459C6046-E0B9-4141-AE09-4A7B2BEEBF39 Q27333771-CC31D9C1-2FAF-4702-A6FE-771E082C5343 Q28730933-970D948E-9CB6-425D-828A-0F67AAFA4DF4 Q28804076-2C8F7964-831C-4623-A414-7B132FC31FD8 Q30145640-EF9B410E-5A63-43CD-A8EB-3136FC795BA9 Q30811442-5664DDD1-AA17-4442-BF51-5ACD42B61ACF Q33601655-FE93FE6B-0D38-4820-AC34-D846D86C7C53 Q33799708-62218B4A-53DC-4755-A0D8-EB8022975375 Q34325937-634EFD1D-D2CF-438B-931D-D267C7EAE6DE Q34429257-01CA728E-B76B-4ABC-8B40-3B1181986CEB Q34594111-4EE3B22A-EADA-4629-8140-B3219424E729 Q34776647-BAF088B5-C80D-41D6-81D9-96967BC6E92A Q34999617-108C84B1-E87C-4779-9648-2DCBA052B6BE Q35069160-BDA473E3-C079-4473-979D-D5E83E433E03 Q35122823-53943D40-80EC-4F8F-9DFB-52A2132F8A5B Q35862258-8D1B93A9-74C7-4256-8F58-81E2D004A18B Q35870061-D01B8852-3AC7-412E-B717-44875127588B Q36245225-F15820CA-0EDA-4F43-BB50-968C0C6B5E72 Q36524044-055C3D13-1DB8-43B8-929D-BD8136C7C2CC Q36570858-69EADC04-E514-48F3-A34E-0047DDE6A555 Q36686929-748714E2-F2AD-4144-A2D8-6E186D547924 Q37012203-7B31D49D-A21F-44C8-9CAF-CB810B03CB7A Q37135485-9F963D8A-937E-42E8-B34C-02BBCC656486 Q37194776-1296068C-945A-4AF2-98E2-5466E12BDB16 Q37375969-03561027-5DFD-43F8-A014-F28C6BB82F78 Q37384755-F1F34112-A60A-4CB1-A866-25E116651169 Q37646725-AF9822C4-A481-4E3D-980C-27350E7520A5 Q38018508-B22C63E3-5F7D-48F4-A053-198CF29EF07D Q38059753-3B2A44E7-30CF-401D-8D5C-C7D56B5F6FA7 Q38078826-9EB187E3-4361-4675-A39E-DDB88FBE033A Q38156841-E9A1E9AA-86C9-4B72-9CDE-735007D7F017 Q38157816-1606746A-DE8D-4617-AA15-41072964BDA6 Q38158247-0DFA94A4-CF62-42BC-B205-767ABB8EBC35 Q38271711-0528DF8D-A0B0-40BE-A8DD-DA654178302B

P2860

Field effectiveness of vaccination against tick-borne encephalitis.

http://www.wikidata.org/entity/Q43040713

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Field effectiveness of vaccination against tick-borne encephalitis.

@en

Field effectiveness of vaccination against tick-borne encephalitis.

@nl

type

label

Field effectiveness of vaccination against tick-borne encephalitis.

@en

Field effectiveness of vaccination against tick-borne encephalitis.

@nl

prefLabel

Field effectiveness of vaccination against tick-borne encephalitis.

@en

Field effectiveness of vaccination against tick-borne encephalitis.

@nl

P1433

Q43040713-91703A94-0622-4BD0-B5FE-A2DF964D07D8

P1476

Q43040713-02C01E76-F758-42CE-933D-304FD9DDAC29

P2093

Q43040713-7F64DDC4-DEA2-428C-98FA-E596783550A2

Q43040713-94FF42AC-9767-47DC-8F9A-DB7E3BFF0F71

Q43040713-CDE5E67F-B8E2-4E71-B279-F820B9B951D0

P304

Q43040713-06100D4A-5FA5-4357-B04B-59AB9AD3A151

P31

Q43040713-4418616D-C316-4A98-857E-BB244C18B1A5

P356

Q43040713-66B501BF-5EBA-4F0E-B513-B49B28DDC1DD

P407

Q43040713-5F7A9EE5-5F87-463B-95F6-BE457BAF8B83

P433

Q43040713-F3F7A0BF-7742-4B25-8585-577F7462A891

P478

Q43040713-23B5A2C7-6EB2-46CE-BAF1-66A863C69A34

P50

Q43040713-9F6675FA-E02E-4F66-A1AE-4133D676A941

P577

Q43040713-3749ACB3-A2C9-4B77-B9CA-C9CBDC9E096F

P698

Q43040713-237CFEB0-981F-4C19-BDB2-2C7C2AA6ED90

P356

J.VACCINE.2007.08.024

P1433

P1476

Field effectiveness of vaccination against tick-borne encephalitis.

@en

P2093

Astrid Essl

http://www.w3.org/2001/XMLSchema#string

Franz X Heinz

http://www.w3.org/2001/XMLSchema#string

Heidemarie Holzmann

http://www.w3.org/2001/XMLSchema#string

P304

7559-7567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2007.08.024

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17869389

http://www.w3.org/2001/XMLSchema#string